Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Sandvik in connection with a EUR 500 million loan from the European Investment Bank (EIB)Vinge has advised Sandvik in connection with a EUR 500 million loan from the European Investment Bank (EIB)
Mandate

Vinge has advised Sandvik in connection with a EUR 500 million loan from the European Investment Bank (EIB)

January 20, 2023 Banking and Finance

Vinge has advised Sandvik AB (publ) and Sandvik Treasury AB (publ) in connection with the entry into of a EUR 500 million loan agreement with the European Investment Bank (EIB). The loan will support Sandvik’s investments in research and development (R&D), which include advanced solutions in component manufacturing as well as solutions for electrification and automation in mining and infrastructure.

The loan has a seven-year tenor and will support Sandvik’s R&D investment plans until 2025.

Sandvik is a global, high-tech engineering group providing solutions that enhance productivity, profitability and sustainability for the manufacturing, mining and infrastructure industries.

Vinge’s team consisted of Albert Wållgren, Arvid Weimers and Karl-Gustaw Tobola.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026